BioVersys (private company)

See something wrong or missing? Let us know
Offices:Basel
Industry:Biotech
Business model:B2B

BioVersys is a Switzerland-based pharmaceutical company developing BV100, a potential breakthrough hospital antibiotic to treat serious infections caused by carbapenem resistant Acinetobacter baumannii (CRAB) in indications of ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP) and bloodstream infections (BSI).

Investors: we tracked 2 investors

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

values in USD

Investments 60.96M


You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Top